Since June 2023, a new term has been making the rounds: metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as “non-alcoholic fatty liver disease” (NAFLD). The renaming emphasises the association with metabolic conditions such as obesity, type 2 diabetes (T2D), and cardiometabolic risk factors. Now a new interdisciplinary European guideline has been published that defines MASLD as the combination of steatotic liver disease with one or more cardiometabolic risk factors in the absence of other causes such as alcohol consumption.

But apart from the name, what else has changed?